The estimated Net Worth of Christopher M Starr is at least $685 Тысяча dollars as of 31 December 2023. Christopher Starr owns over 2,533 units of Monopar Therapeutics Inc stock worth over $62,071 and over the last 21 years Christopher sold MNPR stock worth over $622,620.
Christopher has made over 21 trades of the Monopar Therapeutics Inc stock since 2003, according to the Form 4 filled with the SEC. Most recently Christopher exercised 2,533 units of MNPR stock worth $6,079 on 31 December 2023.
The largest trade Christopher's ever made was selling 33,000 units of Monopar Therapeutics Inc stock on 21 August 2003 worth over $297,000. On average, Christopher trades about 3,592 units every 266 days since 2003. As of 31 December 2023 Christopher still owns at least 25,863 units of Monopar Therapeutics Inc stock.
You can see the complete history of Christopher Starr stock trades at the bottom of the page.
Christopher's mailing address filed with the SEC is 1000 SKOKIE BLVD SUITE 350, , WILMETTE, IL, 60091.
Over the last 5 years, insiders at Monopar Therapeutics Inc have traded over $1,830,000 worth of Monopar Therapeutics Inc stock and bought 895,199 units worth $6,154,669 . The most active insiders traders include Michael J Brown, Diane Hendricks и Pharma Llc Mazar Andrew Pau.... On average, Monopar Therapeutics Inc executives and independent directors trade stock every 15 days with the average trade being worth of $32,266. The most recent stock trade was executed by Andrew Cittadine on 30 June 2024, trading 8,952 units of MNPR stock currently worth $21,485.
monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.
Monopar Therapeutics Inc executives and other stock owners filed with the SEC include: